PF-Atlas › Drugs › Galectin-3 Inhibition

Galectin-3 Inhibition

Idiopathic Pulmonary Fibrosis · Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release

Mechanism
Inhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β release
Development stage
Phase II
Evidence level
Level 2 (Phase II)
Developer
Galecto Biotech

Overview

Inhaled delivery directly to lung. Galectin-3 is elevated in IPF BAL fluid and drives macrophage-to-myofibroblast activation. Phase IIb results pending.

Explore related

Treatment profileInhaled galectin-3 inhibitor blocks fibroblast activation and TGF-β releaseAll trialsResearch
Medical disclaimer. This page summarizes research about Galectin-3 Inhibition for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.